Cargando…
Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion
TP53 deletion (ΔTP53) in myeloma is known to be a high-risk finding associated with poorer prognosis. The prognostic impact of underlying cytogenetic heterogeneity in patients with myeloma associated with ΔTP53 is unknown. We studied 90 patients with myeloma associated with ΔTP53 identified by inter...
Autores principales: | Hao, Suyang, Lin, Pei, Medeiros, L Jeffrey, Fang, Lianghua, Carballo-Zarate, Adrian A, Konoplev, Sergej N, Sargent, Rachel L, Weber, Donna M, Thomas, Sheeba K, Manasanch, Elisabet E, Orlowski, Robert Z, Lu, Xinyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628266/ https://www.ncbi.nlm.nih.gov/pubmed/28664940 http://dx.doi.org/10.1038/modpathol.2017.63 |
Ejemplares similares
-
The Leukemic Phase of ALK-Negative Anaplastic Large Cell Lymphoma Is Associated with CD7 Positivity, Complex Karyotype, TP53 Deletion, and a Poor Prognosis
por: Qiu, Lianqun, et al.
Publicado: (2021) -
A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
por: Lee, Hans C., et al.
Publicado: (2019) -
Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma
por: Patel, Krina K., et al.
Publicado: (2022) -
P814: ANALYSIS OF TP53 ALTERATIONS BY WGS REVEALS BIALLELIC 17P DELETIONS IN MULTIPLE MYELOMA
por: Truger, Marietta, et al.
Publicado: (2023) -
Deregulation and Targeting of TP53 Pathway in Multiple Myeloma
por: Jovanović, Katarina K., et al.
Publicado: (2019)